Log In
Print
BCIQ
Print
Print this Print this
 

ABT-719, ZP1480 (formerly AP214)

  Manage Alerts
Collapse Summary General Information
Company Zealand Pharma A/S
DescriptionAlpha-melanocyte-stimulating hormone analog
Molecular Target Melanocortin 1 receptor (MC1R) ; Melanocortin 3 receptor (MC3R)
Mechanism of ActionMelanocortin 1 receptor (MC1R) agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationRenal damage
Indication DetailsPrevent acute kidney injury (AKI) following major cardiac surgery; Treat acute kidney injury (AKI)
Regulatory Designation
Partner AbbVie Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$110.0M

$110.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today